DrugPatentWatch Database Preview
EPZICOM Drug Profile
» See Plans and Pricing
Which patents cover Epzicom, and what generic alternatives are available?
Epzicom is a drug marketed by Viiv Hlthcare and is included in one NDA.
The generic ingredient in EPZICOM is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.
Summary for EPZICOM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 17 |
Clinical Trials: | 21 |
Patent Applications: | 1,872 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for EPZICOM |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EPZICOM |
What excipients (inactive ingredients) are in EPZICOM? | EPZICOM excipients list |
DailyMed Link: | EPZICOM at DailyMed |


Paragraph IV (Patent) Challenges for EPZICOM
Tradename | Dosage | Ingredient | NDA | Submissiondate |
---|---|---|---|---|
EPZICOM | TABLET;ORAL | abacavir sulfate; lamivudine | 021652 | 2007-09-27 |
US Patents and Regulatory Information for EPZICOM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EPZICOM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | Start Trial | Start Trial |
Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | Start Trial | Start Trial |
Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | Start Trial | Start Trial |
Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | Start Trial | Start Trial |
Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EPZICOM
Country | Patent Number | Estimated Expiration |
---|---|---|
Slovenia | 9110782 | Start Trial |
Japan | H01316375 | Start Trial |
Ireland | 900452 | Start Trial |
Finland | 894545 | Start Trial |
Germany | 68924549 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for EPZICOM
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0817637 | SPC/GB05/027 | United Kingdom | Start Trial | SPC/GB05/027: 20050922, EXPIRES: 20191216 |
0817637 | 288 | Finland | Start Trial | |
0817637 | CA 2005 00028 | Denmark | Start Trial | |
0817637 | C300195 | Netherlands | Start Trial | PRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDB AAR ZUURADDITIEZOUT, IN HET BIJZONDER HET HEMISULFAAT, EN LAMIV UDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; REGISTRTION NO/DATE: EU/04/298/001-002 20041217 |
0434450 | 1999C0033 | Belgium | Start Trial | PRODUCT NAME: ABACAVIR SULFATE; NATL. REGISTRATION NO/DATE: EU/1/99/112/001 19990708; FIRST REGISTRATION: CH 55048 19990628 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |